Difference between revisions of "Alpha-methylacyl-CoA racemase"

From Libre Pathology
Jump to navigation Jump to search
Line 31: Line 31:
==Negative==
==Negative==
*[[Clear cell papillary renal cell carcinoma]].
*[[Clear cell papillary renal cell carcinoma]].
==Images==
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- low mag.jpg | Prostatic carcinoma - CK5/6-AMACR - low mag. (WC)
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. mag. (WC)
Image: Prostate carcinoma with inflammation - alt - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. (WC)
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- high mag.jpg | Prostatic carcinoma - CK5/6-AMACR - high mag. (WC)


==See also==
==See also==

Revision as of 19:18, 31 July 2016

Alpha-methylacyl-CoA racemase
Immunostain in short

AMACR positivity in ASAP. CK5/6-AMACR immunostain
Abbreviation AMACR
Synonyms racemase
Subspeciality genitourinary pathology
Normal staining pattern cytoplasmic
Positive prostate carcinoma ~90%, high grade prostatic intraepithelial neoplasia, urothelial carcinoma ~50%, papillary renal cell carcinoma
Negative clear cell papillary renal cell carcinoma (clear cell tubulopapillary RCC)

Alpha-methylacyl-CoA racemase, abbreviated AMACR, is a commonly used immunostain in genitourinary pathology.

General

AMACR converts testosterone to hydrotestosterone.[1]

Positive

Positive or negative

Negative

Images

Image: Prostate carcinoma with inflammation - ck5-6-amacr -- low mag.jpg | Prostatic carcinoma - CK5/6-AMACR - low mag. (WC) Image: Prostate carcinoma with inflammation - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. mag. (WC) Image: Prostate carcinoma with inflammation - alt - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. (WC) Image: Prostate carcinoma with inflammation - ck5-6-amacr -- high mag.jpg | Prostatic carcinoma - CK5/6-AMACR - high mag. (WC)

See also

References

  1. Cai, LQ.; Zhu, YS.; Katz, MD.; Herrera, C.; Baéz, J.; DeFillo-Ricart, M.; Shackleton, CH.; Imperato-McGinley, J. (May 1996). "5 alpha-reductase-2 gene mutations in the Dominican Republic.". J Clin Endocrinol Metab 81 (5): 1730-5. doi:10.1210/jcem.81.5.8626825. PMID 8626825.
  2. Lloyd, MD.; Yevglevskis, M.; Lee, GL.; Wood, PJ.; Threadgill, MD.; Woodman, TJ. (Apr 2013). "α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.". Prog Lipid Res 52 (2): 220-30. doi:10.1016/j.plipres.2013.01.001. PMID 23376124.
  3. Molinié, V.; Balaton, A.; Rotman, S.; Mansouri, D.; De Pinieux, I.; Homsi, T.; Guillou, L. (Jun 2006). "Alpha-methyl CoA racemase expression in renal cell carcinomas.". Hum Pathol 37 (6): 698-703. doi:10.1016/j.humpath.2006.01.012. PMID 16733210.
  4. Langner, C.; Rupar, G.; Leibl, S.; Hutterer, G.; Chromecki, T.; Hoefler, G.; Rehak, P.; Zigeuner, R. (Mar 2006). "Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.". Virchows Arch 448 (3): 325-30. doi:10.1007/s00428-005-0129-6. PMID 16315020.